LBT Innovations Limited
LBT.AX
Australian Securities Exchange0.02
AUD
- -
- -
LBT Innovations Limited
LBT.AX
(Australian Securities Exchange)
Recent
price
0.02
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- LBT Innovations Limited, now operating under the name Clever Culture Systems, is a technology company specializing in automated solutions for microbiology laboratories. The company's core product, the Automated Plate Assessment System (APAS Independence), utilizes artificial intelligence and machine learning software to automate the imaging, analysis, and interpretation of microbiology culture plates following incubation. LBT also offers additional modules such as the APAS-Antimicrobial Resistance (AMR) analysis module, expanding its applications in clinical and pharmaceutical microbiology. The company’s products primarily address clinical pathology laboratories and pharmaceutical quality control markets, serving customers across Australia, the United States, Europe (including the UK and Germany), and Switzerland. Founded in 2013 and headquartered in Adelaide, Australia, LBT Innovations has a strategic presence in key international markets. It initially commercialized its technology through a joint venture named Clever Culture Systems, which became a wholly owned subsidiary in December 2021 following LBT’s acquisition of the remaining 50% equity and shareholder loans from its partner, Hettich Holding, for around AUD 4 million. This consolidation positioned LBT to streamline operations and marketing efforts under the Clever Culture Systems brand. In recent developments, LBT Innovations officially announced the rebranding to Clever Culture Systems in late 2024 to unify its corporate identity with its commercial operations. The company recently completed the sale of its APAS Independence instrument to Bristol Myers Squibb and has established strategic partnerships such as appointing Thermo Fisher Scientific as the exclusive distributor for the APAS system in the U.S. market. These collaborations underscore LBT’s ongoing efforts to scale its global footprint and broaden product adoption. The company continues enhancing its AI-driven platform with new service offerings aimed at improving efficiency and accuracy in microbiology testing environments. LBT Innovations operates within the medical technology and biotech industry, focusing on automation technologies that reduce manual labor and improve diagnostic throughput. Its products are FDA-cleared and uniquely positioned as the only artificial intelligence platform approved for automated microbiology culture plate testing. The business targets clinical diagnostic laboratories, pharmaceutical companies, and other life sciences sectors requiring microbial quality control and culture analysis solutions. Overall, LBT Innovations Limited (ticker: LBT.AX) delivers intelligent automation for microbiology testing through its APAS technology suite, leveraging strategic acquisitions, product advancements, and global distribution partnerships to expand its market presence since its founding in 2013 in Adelaide, Australia.